Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2025-07-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司第六届监事会第三次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a resolution passed at the third meeting of the sixth Supervisory Board of Changchun Baike Biotechnology Co., Ltd. It details the meeting attendance, the agenda discussed, and the voting results regarding the use of idle raised funds for temporary working capital. The document references compliance with company law and internal regulations, and it explicitly states the resolution and voting outcome. It also refers to a related announcement (2025-025) published on the Shanghai Stock Exchange website. The content is a meeting resolution announcement rather than a full financial report, audit, or management discussion. It does not contain financial statements or detailed financial analysis. The document is short (804 characters) and is a formal announcement of a board meeting resolution, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like MANG (management changes) or CAP (capital updates).
2025-07-25 Chinese
长春百克生物科技股份公司关于自愿披露流感病毒裂解疫苗（BK-01佐剂）临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun Baike Biotechnology Co., Ltd. regarding the approval of a clinical trial application for an influenza virus split vaccine (BK-01 adjuvant) by the National Medical Products Administration. It includes details about the approval notice, vaccine description, potential impact on the company, and risk warnings. The document is short (1326 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed investor presentation content. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about clinical trial approval and risk disclosure.
2025-06-19 Chinese
长春百克生物科技股份公司2024年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an "annual equity distribution implementation announcement" for the year 2024 by Changchun Baike Biological Technology Co., Ltd. It details the dividend distribution plan, including the dividend per share, relevant dates (record date, ex-dividend date, payment date), and tax treatment for different shareholder categories. The document also states that the dividend plan was approved at the 2024 annual shareholders meeting held on May 13, 2025. The content is focused on the announcement of dividend amounts and payment details rather than the full annual report or financial statements. The document length is 2692 characters, which is relatively short and consistent with a dividend announcement rather than a full report. Therefore, this document fits the category of "Notice of Dividend Amount" (DIV).
2025-06-10 Chinese
长春百克生物科技股份公司关于自愿披露重组带状疱疹疫苗（CHO细胞）临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Changchun Baike Biotechnology Co., Ltd. regarding the approval of a clinical trial application for a recombinant shingles vaccine (CHO cells) by the National Medical Products Administration. It includes details about the approval notice, vaccine description, potential impact on the company, and risk warnings. The document is relatively short (1412 characters) and serves as a regulatory announcement about a clinical trial approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention the release or availability of a report. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a clinical trial approval and related risk disclosures that do not fit into other specific categories.
2025-06-04 Chinese
长春百克生物科技股份公司关于参加2025年吉林辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online investor reception day event organized by securities associations. It mentions the date and time of the event and lists company representatives who will communicate with investors about the 2024 annual performance, governance, strategy, and operations. The document is short (583 characters) and does not contain any financial statements or detailed financial data. It is not a report itself but an announcement of an event for investor communication. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-05-19 Chinese
长春百克生物科技股份公司2024年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2024 Annual General Meeting (AGM) of Changchun Baike Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including the 2024 annual report, director and supervisor remuneration, and auditor appointment. The document is not the annual report itself but the official announcement of the shareholder meeting decisions and voting outcomes. The length is under 5,000 characters and it focuses on the AGM resolutions and voting results, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-13 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.